Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63-KH in persistent PKDL
NCT02894008Phase 2Completed
- Sponsor
- University of York
- Start
- Nov 2016
- Primary completion
- Sep 2019
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ChAd63-KH in Post kala-azar dermal leishmaniasis (PKDL), sponsored by University of York. Started Nov 2016; status: completed.
02
Drugs
ChAd63-KH
03
Conditions
Post kala-azar dermal leishmaniasis (PKDL)
Beyond the preview
Go deeper on NCT02894008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02894008.